Evaluation of Accountability Measurement Tool in Patients with Psoriasis

A Validation Study

Su, Jennifer J.; Cline, Abigail; Bashyam, Arjun M.; Masicampo, E. J.; Ip, Edward H.; Feldman, Steven R.

Published in:
Dermatology and Therapy

DOI:
10.1007/s13555-020-00376-w

Publication date:
2020

Document version
Final published version

Document license
CC BY-NC

Citation for published version (APA):
Su, J. J., Cline, A., Bashyam, A. M., Masicampo, E. J., Ip, E. H., & Feldman, S. R. (2020). Evaluation of Accountability Measurement Tool in Patients with Psoriasis: A Validation Study. Dermatology and Therapy, 10(3), 495–502. https://doi.org/10.1007/s13555-020-00376-w

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Evaluation of Accountability Measurement Tool in Patients with Psoriasis: A Validation Study

Jennifer J. Su · Abigail Cline · Arjun M. Bashyam · E. J. Masicampo · Edward H. Ip · Steven R. Feldman

Received: February 26, 2020 / Published online: April 16, 2020 © The Author(s) 2020

ABSTRACT

Introduction: The role of accountability in promoting patient adherence to medication is not well characterized. An accountability measurement tool (AMT) has been developed to quantify accountability but has not been investigated for use with patients with skin disease. We aim to test the reliability and validity of the AMT for patients with psoriasis.

Methods: A 12-item AMT was used for patients with psoriasis. English-speaking adults with psoriasis who were expected to continue their medication were asked to complete the questionnaire. Reliability was measured using Cronbach’s alpha. Validity was measured using Pearson’s correlation coefficient and t-tests between the AMT and other validated scales measuring fear of negative evaluation and self-regulation.

Results: A total of 30 patients were recruited for this study. The AMT demonstrated excellent internal consistency (Cronbach’s $\alpha = 0.86$). Total accountability positively correlated with fear of negative evaluation ($r = 0.59$), autonomous motivation ($r = 0.46$), introjected regulation ($r = 0.60$), and external regulation ($r = 0.57$), demonstrating good convergent validity. Divergent validity was supported by nonsignificant associations between psoriasis accountability and age, gender, race, education level, years with physician, and amotivation.
Conclusions: The AMT has been further validated for measuring accountability in patients with psoriasis.

Keywords: Accountability; Adherence; Patient behavior; Psoriasis; Questionnaire; Reliability; Self-efficacy; Self-determination theory; Validity

**Key Summary Points**

**Why carry out this study?**

Accountability plays a key role in adherence.

The accountability measurement tool (AMT) has been developed and validated for use in chronic diseases but has not been investigated for use with patients with skin disease.

**What was learned from this study?**

The AMT appears to have sufficient reliability and validity to assess accountability in our sample of patients with psoriasis.

The AMT provides a foundation for studies to develop and test new interventions to improve accountability in dermatology, where adherence to therapy is poor.

**INTRODUCTION**

Poor adherence to medication is ubiquitous in dermatology. In particular, patients with psoriasis tend to struggle with their prescribed therapies. With more than 90% of psoriasis patients having a chronic course and therefore requiring continual control of disease activity, adherence to treatment is crucial for successful management [1]. Poor adherence to topical treatment results in inadequate treatment, persistent disease, and continued suffering [2]. This can lead to escalation of treatment to toxic systemic agents (such as methotrexate and cyclosporine) or extremely costly medications such as biologics. The very poor long-term adherence of psoriasis patients makes psoriasis an exceptionally good model system for studying the factors that contribute to self-efficacy and self-management of chronic disease [3].

We have previously demonstrated that the self-management of psoriasis can be enhanced by external factors such as increasing the frequency of office visits [4–6]. Psoriasis treatments are used more frequently around the time of office visits [3]. The increased use of treatment around the time of office visits is seen across a wide range of chronic conditions [7–11]. The accountability derived from the expectation of a social interaction between the patient and the health care provider may affect patients’ motivation to adhere to treatment.

Accountability is an internal, psychobehavioral construct involving an expected social interaction [12]. Anticipation of a social interaction tends to promote accountability and, in turn, the self-regulation of behavior. The social interaction between physician and patient is no exception. A sense of accountability may mediate the effects of increasing office visits, which may explain why adherence to therapy increases leading up to a doctor’s visit [13]. This concept has started to become incorporated into adherence models and in clinical practice [12]. By understanding the accountability and psychology by which office visits act, we could create better approaches that modify accountability. To understand the effects of accountability on adherence, a reliable tool to measure the construct must be created and applied to dermatology.

We previously developed and validated an accountability measurement tool (AMT) for patients with any disease lasting more than 3 months [14]. However, whether it is generalizable to patients with a specific chronic disease is unknown. In this study, we used the AMT on patients with psoriasis to test the reliability and validity of the AMT for a specific disease.

**METHODS**

The Wake Forest University School of Medicine Institutional Review Board (IRB) determined that...
this study met the regulatory criteria for exemption from IRB oversight, and that this research meets criteria for a waiver of written (signed) consent according to 45 CFR 46.117(c)(2).

**Patients**

The primary validation of the AMT had 292 respondents [14]. For this study, we aimed to recruit 10% of this sample size to confirm its utility in a specific disease population. Participants were recruited at the clinic if they met the following inclusion criteria: subjects with psoriasis and a working knowledge of English who were prescribed at least one medication for the past month and are expected to continue for another month, who have a regular physician they have seen at least twice during the past 2 years, and aged 18 years or older [15]. Those who agreed to participate were asked to fill out the survey on a tablet.

**Accountability Measurement Tool**

The AMT divides accountability into two categories based on the self-determination theory and Bandura’s theory of self-efficacy: autonomous accountability and controlled accountability [14, 16]. Autonomous accountability refers to one’s internal desire to please a physician. Controlled accountability is based on one’s tendency to avoid shame and guilt from others [12]. Six items fall under autonomous accountability, and six items fall under controlled accountability. Items were measured using a Likert scale (from 1 = “Strongly disagree” to 5 = “Strongly agree”) to detect small differences.

**Psychometric Evaluation**

The items were compiled into a survey instrument that also included the following measures used to assess the reliability and validity of the adapted scale.

**Fear of Negative Evaluation**

The brief fear of negative evaluation (BFNE) scale is used to measure fear of negative evaluation [17]. The previous study, in which the AMT was developed, used a 12-item variant consisting of 4 reverse-worded and 8 straightforwardly worded questions. Instead, in the present study, we replaced the full BFNE scale with an eight-item variant consisting of only the straightforwardly worded questions (BFNE-S). This version is reliable and more concise than other versions [18]. Responses were measured using a Likert scale (from 1 = “Not at all characteristic of me” to 5 = “Extremely characteristic of me”). The BFNE-S scores range from 8 to 40, with higher scores positively correlating with fear of negative evaluation. A score of at least 25 demonstrates clinically significant social anxiety [18].

**Treatment Self-Regulation**

The treatment self-regulation questionnaire (TSRQ) is commonly used to study behavioral regulation in healthcare settings. The TSRQ was modified to assess why patients with psoriasis take their medications. The 15-item TSRQ evaluates behavioral regulation using four subscales: autonomous motivation (6), introjected regulation (2), external regulation (4), and amotivation (3) [19]. Responses were measured using a Likert scale (from 1 = “Not at all true” to 7 = “Very true”). The TSRQ has been validated across multiple sites and various health behaviors [19].

**Other Variables**

Standard survey questions assessing age, sex, race, ethnicity, education level, and duration of the physician–patient relationship in years were included. Whether the patient had a past disagreement or dispute with his/her physician and whether the patient was satisfied with his/her physician were also evaluated (yes/no).

**Statistical Analyses**

Descriptive statistics were calculated for the surveyed sample and the AMT scores. Cronbach’s $\alpha$ reliability test was used to estimate the internal consistency of the whole accountability questionnaire in addition to each subscale (autonomous accountability and controlled...
Values above 0.7 are considered reliable [20].

Validity was tested using bivariate correlation analyses and t-tests. Construct validity was assessed by examining the convergent and divergent validity of numerous variables. Based on the previous AMT results, we predicted that total, autonomous, and controlled accountability would be related to the BFNE-S and the TSRQ autonomous motivation, introjected regulation, external regulation, and amotivation scores (convergent validity). We also predicted that age, gender, education level, and duration with provider would not be significantly associated with the psoriasis AMT (divergent validity). All statistical tests were two-tailed, and a p-value < 0.05 was considered significant. The Statistical Package for the Social Sciences (SPSS) software was used to execute statistical tests.

RESULTS

Sample Characteristics

A total of 30 patients participated in the study (Table 1). The average age (standard deviation, SD) of the sample was 54 (14) years. A majority of the patients were White (83%) and female (57%). Patients spent an average of 8.2 (7.4) years with their medical provider. No participant reported a past dispute with his/her physician. All participants reported satisfaction with their physicians. The average total accountability score for psoriasis patients was 47 (7.8). The mean fear of negative evaluation score was 16 (8.7), indicating the sample was not socially anxious. Regarding the average TSRQ subscale scores, autonomous motivation was 38 (4.9); introjected regulation was 9.3 (4.3); external regulation was 11 (7.1); and amotivation was 8.5 (4.8) (Table 1).

| Table 1 Characteristics of total sample |
|----------------------------------------|
| Variable                               | Total (%) |
| n                                      | 30         |
| Age in years (SD)                      | 54 (14)    |
| Gender (female)                        | 17 (57%)   |
| Race                                   |            |
| White                                  | 25 (83%)   |
| Black or African American              | 4 (13%)    |
| Asian                                  | 1 (3.3%)   |
| Ethnicity                              |            |
| Hispanic or Latino                     | 0.0        |
| Level of education                     |            |
| High school                            | 11 (37%)   |
| Technical degree                       | 1 (3.3%)   |
| Associate degree                       | 6 (20%)    |
| Bachelors                              | 8 (27%)    |
| Masters                                | 4 (13%)    |
| Time spent with medical provider in years (SD) | 8.2 (7.4) |
| Past disagreement or dispute with physician | 0.0       |
| Overall satisfied with doctor          | 30 (100%)  |
| Psoriasis accountability (SD)          |            |
| Total                                  | 47 (7.8)   |
| Autonomous accountability              | 25 (3.7)   |
| Controlled accountability              | 22 (5.2)   |
| Brief fear of negative evaluation score (SD) | 16 (8.7) |
| Treatment self-regulation scores (SD)  |            |
| Autonomous motivation                  | 38 (4.9)   |
| Introjected regulation                 | 9.3 (4.3)  |
| External regulation                    | 11 (7.1)   |
| Amotivation                            | 8.5 (4.8)  |

Internal Consistency

The 12-item scale demonstrated good internal consistency overall (Cronbach’s α = 0.86). Autonomous and controlled accountability also showed good internal consistency (Cronbach’s α = 0.75 and 0.82, respectively).
Among our sample, the BFNE-S was very reliable (Cronbach’s \( \alpha = 0.94 \)). Regarding the TSRQ, autonomous motivation (Cronbach’s \( \alpha = 0.74 \)), introjected regulation (Cronbach’s \( \alpha = 0.74 \)), and external regulation (Cronbach’s \( \alpha = 0.87 \)) showed good reliability; however, amotivation did not show good internal consistency (Cronbach’s \( \alpha = 0.60 \)).

**Construct Validity**

Correlations between the AMT and other factors were measured using Pearson’s correlation coefficient (Table 2). Accountability positively correlated with fear of negative evaluation \( (r = 0.59) \), autonomous motivation \( (r = 0.46) \), introjected regulation \( (r = 0.60) \), and external regulation \( (r = 0.57) \), demonstrating convergent validity.

The correlations between the AMT and the TSRQ subscales were also analyzed for validity. As predicted, total accountability correlated with autonomous motivation \( (r = 0.46) \), introjected regulation \( (r = 0.60) \), and external regulation \( (r = 0.57) \). However, total accountability did not show significant correlation with amotivation, which was not predicted. Similarly, autonomous accountability had significant associations with autonomous motivation \( (r = 0.51) \), introjected regulation \( (r = 0.56) \), and external regulation \( (r = 0.54) \) but not amotivation. Consistent with previous findings, controlled accountability correlated with introjected \( (r = 0.52) \) and external regulation \( (r = 0.49) \). In contrast to our predictions, it did not significantly correlate with autonomous motivation or amotivation.

Divergent validity was supported by non-significant associations between accountability and age, gender, race, education level, and years with physician.

**DISCUSSION**

Overall, the AMT and its subscales showed excellent internal consistency when used for patients with psoriasis. The accountability measures for patients with psoriasis showed consistencies with the original AMT. Both found positive associations between accountability and fear of negative evaluation [14]. Although we did not predict the lack of association between accountability and amotivation, these results were not unexpected. The previous validation of the AMT showed a weak correlation between amotivation and accountability \( (r = 0.38, p = 0.01) \) [14]. The lack of significant correlation between accountability and amotivation suggests that patient accountability stems from an external (e.g., from their physician) and/or internal (i.e., from oneself) drive to use one’s medication. Ultimately, the accountability between patient and healthcare provider appears to have underlying intention. Another difference is how controlled accountability is only associated with introjected and external regulation. However, this is unsurprising as introjected and external regulation are forms of controlled motivation [21]. Age, gender, education level, and reported duration with physician had no significant associations with accountability or any of its factors. The results from this study further support accountability as an independent construct [14].

By creating a validated research tool to measure the psychosocial construct of accountability, we can elucidate how accountability affects dermatology patients’ behavior. We may use this measure to evaluate interventions aimed to improve accountability and thereby adherence to dermatological treatment. Previous suggestions to increase the frequency office visits are not practical for patients who would have to miss work and pay more copays. An example of a sensible solution is to encourage patients to communicate with their physicians through patient portals. About 52% of patients are already offered access to their medical record by their health provider [22]. Instructing patients to report their progress by messaging their providers online creates the expectation of a social interaction, thus promoting accountability. Therefore, utilizing the concept of accountability can create less-costly highly feasible approaches to improving patient adherence.

This study presents multiple limitations. First, the small sample size did not produce variation in some responses. As a result,
Table 2: Intercorrelations between variables to demonstrate construct validity

|                  | Accountability | Age | Gender | Race | Education | Physician–patient relationship duration | BFNE-S | Autonomous motivation | Introjected regulation | External regulation | Amotivation Autonomous acct. | Controlled acct. |
|------------------|----------------|-----|--------|------|-----------|------------------------------------------|--------|-----------------------|----------------------|----------------------|-----------------------------|-------------------|
| Age              | 0.19           | 0.05| 0.22   | 0.34 | -0.35     | 0.20                                     | 0.34   | 0.33                  | 0.50                 | 0.57                  | 0.59                        | 0.57              |
| Gender           | -0.34          | 0.06| 0.21   | 0.34 | -0.34     | 0.20                                     | 0.34   | 0.33                  | 0.50                 | 0.57                  | 0.59                        | 0.57              |
| Race             | 0.02           | 0.18| 0.00   | -0.19| 0.12      | -0.05                                    | -0.06  | -0.06                 | -0.06                | -0.06                 | -0.06                       | -0.06             |
| Education        | -0.02          | -0.06| 0.04   | 0.08 | 0.12      | 0.14                                     | -0.33  | -0.33                 | -0.33                | -0.33                 | -0.33                       | -0.33             |
| Physician–patient relationship duration | 0.09 | 0.08 | 0.10 | 0.14 | -0.04 | 0.06 | 0.06 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| BFNE-S           | 0.59           | 0.57| 0.57   | 0.57 | 0.57      | 0.57                                     | 0.57   | 0.57                  | 0.57                 | 0.57                  | 0.57                        | 0.57              |
| Autonomous motivation | 0.59          | 0.59| 0.59   | 0.59 | 0.59      | 0.59                                     | 0.59   | 0.59                  | 0.59                 | 0.59                  | 0.59                        | 0.59              |
| Introjected regulation | 0.59         | 0.59| 0.59   | 0.59 | 0.59      | 0.59                                     | 0.59   | 0.59                  | 0.59                 | 0.59                  | 0.59                        | 0.59              |
| External regulation | 0.59          | 0.59| 0.59   | 0.59 | 0.59      | 0.59                                     | 0.59   | 0.59                  | 0.59                 | 0.59                  | 0.59                        | 0.59              |
| Amotivation Autonomous acct. | 0.59          | 0.59| 0.59   | 0.59 | 0.59      | 0.59                                     | 0.59   | 0.59                  | 0.59                 | 0.59                  | 0.59                        | 0.59              |
| Controlled acct. | 0.59           | 0.59| 0.59   | 0.59 | 0.59      | 0.59                                     | 0.59   | 0.59                  | 0.59                 | 0.59                  | 0.59                        | 0.59              |

*Correlation significant at the 0.05 level (two-tailed)
**Correlation significant at the 0.01 level (two-tailed)

BFNE-S, brief fear of negative evaluation straightforward scale.

Values shown are $r$-values.
analyses could not be performed to determine whether ethnicity, prior dispute with the physician, and physician satisfaction correlated with our measure of accountability. Due to the small sample size, these results should be interpreted with caution. Second, the psoriasis-specific AMT was not analyzed for its test–retest reliability; however, the original AMT demonstrated high temporal stability.

CONCLUSIONS

The AMT provides a foundation for studies to develop and test new interventions to improve accountability in dermatology, where adherence to therapy is poor. Future studies should recruit a larger sample of patients and explore the use of AMT for other chronic skin conditions. Future studies should also add a measure of adherence to better understand how accountability is correlated patient adherence. All in all, the AMT was further validated for measuring accountability in patients with psoriasis.

ACKNOWLEDGEMENTS

We would like to thank the patients who participated in this study. We would also like to thank Dr. Jesús Alberto Cárdenas de la Garza and Dr. Stephanie Cohen for assisting with data collection.

Funding. No funding or sponsorship was received for this study or publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures. Steven R. Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Quient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majoriy owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. He is also a member of the journal’s editorial board. Jennifer J. Su, Abigail Cline, Arjun M. Bashyam, E. J. Masicampo, and Edward H. Ip have nothing to disclose.

Compliance with Ethics Guidelines. The Wake Forest University School of Medicine Institutional Review Board (IRB) determined that this study met the regulatory criteria for exemption from IRB oversight, and that this research meets criteria for a waiver of written (signed) consent according to 45 CFR 46.117(c)(2).

Data Availability. The data supporting the results reported in this article were generated during the study and are available from the corresponding author by request.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
REFERENCES

1. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. S3-Guidelines for the therapy of psoriasis vulgaris. J German Soc Dermatol JDDG. 2006;4(2):S1–126.

2. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. JAMA Dermatol. 2007;143(7):912–5.

3. Alinia H, Moradi Tuchayi S, Smith JA, Richardson IM, Jaros SC, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–64.

4. Bass AM, Anderson KL, Feldman SR. Interventions to increase treatment adherence in pediatric atopic dermatitis: a systematic review. J Clin Med. 2015;4(2):231–42.

5. Heaton E, Levender MM, Feldman SR. Timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions. J Dermatol Treatment. 2013;24(2):82–8.

6. Sagransky MJ, Yentzer BA, Williams LI, Clark AR, Taylor SL, Feldman SR. A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. Arch Dermatol. 2010;146(12):1428–30.

7. Al-Daken LI, Eshah NF. Self-reported adherence to therapeutic regimens among patients with hypertension. Clin Exp Hypertens. 2017;39(3):264–70.

8. Bidwal M, Lor K, Yu J, Ip E. Evaluation of asthma medication adherence rates and strategies to improve adherence in the underserved population at a Federally Qualified Health Center. Res Social Adm Pharm. 2017;13(4):759–66.

9. Garcia Diaz E, Ramirez Medina D, Garcia Lopez A, Morera Porras OM. Determinants of adherence to hypoglycemic agents and medical visits in patients with type 2 diabetes mellitus. Endocrrol Diabetes Nutr. 2017;64(10):531–8.

10. Shah A, Yentzer BA, Feldman SR. Timing of return office visit affects adherence to topical treatment in patients with atopic dermatitis: an analysis of 5 studies. Cutis. 2013;91(2):105–7.

11. Taber DJ, Fleming JN, Fominaya CE, Gebregziabher M, Hunt KJ, Srinivas TR, et al. The impact of health care appointment non-adherence on graft outcomes in kidney transplantation. Am J Nephrol. 2017;45(1):91–8.

12. Oussedik E, Foy CG, Masicampo EJ, Kammrath LK, Anderson RE, Feldman SR. Accountability: a missing construct in models of adherence behavior and in clinical practice. Patient Prefer Adher. 2017;11:1285–94.

13. Feldman SR, Camacho FT, Kammrath J, Carroll CI, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57(1):81–3.

14. Oussedik ECA, Su JJ, Masicampo EJ, Kammrath LK, Ip E, Feldman SR. Accountability in patient adherence. Patient Prefer Adher. 2019;13:1511–7.

15. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–45.

16. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84(2):191–215.

17. Leary MR. A brief version of the fear of negative evaluation scale. Pers Soc Psychol Bull. 1983;9(3):371–5.

18. Carleton RN, Collimore KC, McCabe RE, Antony MM. Addressing revisions to the Brief Fear of Negative Evaluation scale: measuring fear of negative evaluation across anxiety and mood disorders. J Anxiety Disorder. 2011;25(6):822–8.

19. Levesque CS, Williams GC, Elliot D, Pickering MA, Bodenhamer B, Finley PJ. Validating the theoretical structure of the Treatment Self-Regulation Questionnaire (TSRQ) across three different health behaviors. Health Educ Res. 2006;22(5):691–702.

20. Bland JM, Altman DG. Statistics notes: Cronbach’s alpha. BMJ. 1997;314(7080):572.

21. Levesque CS, Williams GC, Elliot D, Pickering MA, Bodenhamer B, Finley PJ. Validating the theoretical structure of the Treatment Self-Regulation Questionnaire (TSRQ) across three different health behaviors. Health Educ Res. 2007;22(5):691–702.

22. Patel V, Johnson C. Individuals’ use of online medical records and technology for health needs. ONC Data Brief. 2018;2018:40.